Aerie Pharmaceuticals (AERI) has been under a strong bear grip, hence the stock is down -0.86% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 3.08% in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 3.72% in the last 1 week, and is up 5.83% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Aerie Pharmaceuticals (NASDAQ:AERI): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $18.03 and $17.50 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $18.39. The buying momentum continued till the end and the stock did not give up its gains. It closed at $18.14, notching a gain of 1.28% for the day. The total traded volume was 1,258,328 . The stock had closed at $17.91 on the previous day.
The stock has recorded a 20-day Moving Average of 3.49% and the 50-Day Moving Average is 5.62%. Aerie Pharmaceuticals, Inc. is up 9.54% in the last 3-month period. Year-to-Date the stock performance stands at -25.5%.
Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Companys primary product candidates, triple-action Rhopressa and quadruple-action Roclatan, are once-daily eye drops. The Companys product candidate, once-daily, quadruple-action Roclatan, is a single drop fixed-dose combination of Rhopressa and latanoprost. Rhopressa inhibits Rho Kinase (ROCK) and the norepinephrine transporter (NET), which are both biochemical targets for lowering intraocular pressure (IOP). The Companys Rhopressa product candidate was in Phase III stage of development. The Company has completed the Roclatan Phase IIb clinical trial. The Company is also in the preclinical development stage with AR-13533, its second-generation ROCK/NET inhibitor.